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An important maxim in treating patients with HIV is that 
the first regimen is your best chance for success. Get it 
right the first time. Recent data show that the response 
of children to antiretroviral therapy (ART) both overseas 
and locally has been phenomenal.1-4 Nevertheless, 
inevitably, increasing numbers of children will require a 
second-line regimen. It is therefore important that we 
have an approach to changing therapy.
There are two main reasons for changing ART – toxicity 
or intolerance, and failure of the current regimen. Other 
reasons include poor adherence (often improved with 
alternative antiretrovirals (ARVs)) and emergence of 
more effective or safer regimens.
TOXICITY OR INTOLERANCE
See the Guidelines for Antiretroviral Therapy in Children, 
p. 32 of this issue. When a patient exhibits intolerance 
to or toxicity from a single drug, the offending drug can 
often be replaced, e.g. replacing zidovudine (AZT) with 
abacavir (ABC) for bone marrow toxicity caused by AZT. 
Rarely, a reduction in dosage may be considered as long 
as the reduced dose is still in the therapeutic range.
For severe toxicity such as lactic acidosis or ABC hyper-
sensitivity reaction, all ART should be stopped until the 
patient recovers. Only then can one cautiously restart 
ART. The offending agent should be switched for one 
that does not cause the same reaction. 
FAILURE OF CURRENT REGIMEN
Ideally one should not change therapy on the basis of a 
single viral load (VL) or CD4 count.
Before changing ART, a thorough assessment of ad-
herence issues should be made. Adherence is the most 
important factor determining the success of an ART 
regimen.5-7 Adherence issues must be resolved before 
changing therapy.
The US Public Health Service Guidelines8 lists three types 
of failure of an antiretroviral regimen – virological, im-
munological and clinical failure (Fig. 1).
Unfortunately there are few paediatric data on when 
to change ART. PENPACT1, a study in Europe and the 
USA, is comparing changing ART at a VL of 1 000 versus 
30 000 copies/ml. Their results will be presented at the 
World AIDS Congress in 2010. The South African guide-
lines recommend changing regimens when the VL is re-
peatedly above 1 000 copies/ml. Some paediatric experts 
would not change the therapy until the VL was repeat-
edly >5 000 - 10 000 copies/ml. Intervention does not 
necessarily mean a change of regimen. It may involve 
resolving adherence issues or changing to a holding 
strategy. With a persistently elevated VL, resistance mu-
tations will accumulate9 and cross-resistance to drugs 
that the patient has not been exposed to will occur.
Isolated VL ‘blips’, e.g. single levels of 50 - 1 000 
copies/ml, are not usually associated with subsequent 
virological failure.10,11 It is important to follow up a blip 
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Please note: The recommendations given in this 
article are only a guide. There is no substitute for 
expert advice when changing ART. Please consult the 
SA HIV Clinicians Society or the author for a list of 
local and overseas experts willing to assist you.
This article is an update of a similar article published in the November 2005 edition of this journal. The rapid pace 
of changes in this field necessitates this update. Alarming numbers of children are failing both first- and second-
line antiretroviral therapy regimens in a very short space of time, underscoring the importance of adhering to the 
basic guiding principles of changing therapy outlined below.
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with another VL after 3 months to exclude virological 
failure.
In children with low CD4 counts, an opportunistic in-
fection can occur before the immune system has recov-
ered and is not an indication to change ART. Similarly, 
with bronchiectasis recurrent lower respiratory tract 
infections are to be expected. Immune reconstitution 
inflammatory syndrome (IRIS) is also not an indication 
to change ART.
CHANGING THERAPY
DIFFERENT SCENARIOS WHEN CHANGING ART
There are three main scenarios when changing ART for 
drug failure.
n    Early failure of a first regimen – there is unlikely to be 
much cross-resistance. A simple choice of a different 
regimen is usually adequate. 
n    Intermediate failure of a first regimen – some cross-
resistance may be present. Genotyping may be help-
ful in ascertaining the degree of cross-resistance.
n    Extensive prior treatment – extensive drug resistance 
is likely.
INITIAL ASSESSMENT
This is important in determining the cause of failure, as 
frequently the same issues will be a barrier to the suc-
cess of a subsequent regimen.
Assessing adherence
Adherence is the most important factor in determining 
the success of an ART regimen.5-7 Virological failure often 
follows poor adherence. Do not change therapy until the 
adherence issues have been resolved. Since the first regi-
men is often the best tolerated, subsequent regimens are 
often not as well tolerated and are likely to exacerbate 
adherence issues. Changing ART is never an emergency 
and is futile without addressing adherence. If adherence 
issues cannot be resolved quickly and you are worried 
about accumulating new resistance mutations, there 
may be a role for a ‘holding strategy’ until the family is 
ready to start the new regimen (see ‘Holding strategies’ 
below). 
Virological considerations:
Incomplete response to therapy:
n    <10 × (1 log10) decrease from baseline VL at 8 - 12 weeks 
n    HIV RNA >400 copies/ml after 6 months or above the level of detection using an ultrasensitive assay 
after 12 months of therapy (some would accept a VL <5 000 copies/ml in a stable patient) 
Viral rebound: 
 Repeated detection of plasma HIV RNA on ultrasensitive PCR assays where viral load was previously un-
detectable. Infrequent episodes of low level viraemia (<1 000 copies/ml) are common and not generally 
reflective of virological failure, whereas repeated or persistent viraemia (>1 000 copies/ml) more probably 
represents viral rebound (some would accept a VL <5 000 copies/ml in a stable patient)
Immunological  considerations:
Incomplete immunological response to therapy: 
n   <5 years of age: Failure to improve CD4% values by ≥5% where CD4% was previously <15%
n    ≥5 years of age: Failure to improve CD4 values by ≥50 cells/µl above baseline where CD4 was previously 
<200 cells/µl within the first year of therapy 
Immunological decline: 
 Sustained decline of 5% in CD4% below pre-therapy baseline at any age, or decline to below pre-therapy 




 Persistent decline in weight-growth velocity despite adequate nutritional support and without other 
explanation
Severe or recurrent infection or illness: 
Recurrence or persistence of AIDS-defining conditions or other serious infections
Fig. 1. Considerations for changing therapy in paediatric patients on antiretroviral therapy.8
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Exclude inadequate drug exposure
Possible causes include:
n    Drug not being ingested, e.g. poor adherence, vomit-
ing, or spitting up of an unpalatable drug such as 
ritonavir.
n    Poor absorption, often in children with chronic diar-
rhoea or malabsorptive states.
n    Increased drug metabolism – children beyond the 
neonatal age have markedly increased drug metabo-
lism compared with adults. Post-marketing research 
often reveals package insert dosages to be inad-
equate. Consult an up-to-date paediatric ART guide-
line for correct dosages.
n    Drug interactions – investigate all medications the 
patient is taking (including over-the-counter drugs 
and ‘herbal’ products) for possible drug interactions 
with ARV agents. Commonly implicated drugs in-
clude rifampicin, anti-epileptics, antimalarials and St 
John’s wort.  
Exclude other causes of a raised VL and/or a lower 
CD4 count
Intercurrent infections, opportunistic infections and im-
munisations may temporarily drop the CD4 count or 
raise the VL.
Ideally one should repeat the CD4 and VL 1 month later 
to ensure a return to baseline.
FACTORS TO CONSIDER WHEN CHANGING 
ANTIRETROVIRAL THERAPY
Expert advice
There is no substitute for expert advice when chang-
ing ART. The field is fraught with pitfalls for the unwary. 
Many patients’ futures have been compromised by poor 
choices when changing therapy. There is always enough 
time to consult with an expert before changing therapy. 
Resistance testing
Only genotypic assays are available in South Africa. Adult 
data reveal a short-term benefit of resistance testing in 
terms of virological response.12,13 Paediatric data are con-
flicting,14-17 but most experts believe that these assays 
have a role in changing ART in the face of resistance. 
Overseas guidelines recommend using resistance testing 
with every change of ART regimen caused by treatment 
failure.8,18 This  is also the recommendation of the  SA 
HIV Clinicians Society,  but prohibitive cost (over R4 000) 
will probably mean that in the South African state sector 
genotyping will only be done (if at all) after failure of 
a second regimen. Apart from the cost, genotyping has 
other limitations, including the following:
n    Genotyping will only give information about the 
current regimen. If a patient has failed a drug in a 
previous regimen, genotyping may therefore falsely 
report susceptibility to that drug.
n    Genotyping should be done while the patient is still 
taking their ‘failing’ regimen or within 4 weeks of 
stopping it.18  
n    Genotyping needs expert interpretation. It requires 
in-depth analysis by someone highly experienced in 
the field who also has all the details of the patient’s 
treatment history. Knowledge of paediatric data and 
formulations are essential for correct advice. 
At least 2 new drugs
Always try to include at least 2 (preferably 3) new or ac-
tive agents.18 One needs to be aware of cross-resistance 
(see below), since what may look like a ‘new agent’ may 
be ineffective as the virus is already resistant to it. Geno-
typing may help to select which drugs in the present 
regimen could be re-used. This does not apply to drugs 
in a previous regimen, as resistance mutations may be 
below the level of detection.
Preferably a new drug class 
Studies have shown that the success of a subsequent 
regimen is increased if it contains an antiretroviral class 
to which the patient has not previously been exposed.19,20 
Two new drug classes, integrase and CCR5 inhibitors, 
should be available locally soon. They will be useful in 
highly experienced patients. 
Do not add one drug to a failing regimen
Adding one drug to a failing regimen will predispose to 
the rapid development of resistance. This is the equiva-
lent of monotherapy, which should generally be avoided 
at all costs. A variant of this is combining an active drug 
with a low genetic threshold for resistance, such as a 
non-nucleoside reverse transcriptase inhibitor (NNRTI) 
or raltegravir (integrase inhibitor), with 2 partially active 
drugs – in this situation the active drug will fail quickly.
Consider cross-resistance
Cross-resistance can be defined as phenotypic resist-
ance to one drug resulting from mutations (genotypic) 
selected by another drug.21 There is no cross-resistance 
between the different ARV classes. In the nucleoside re-
verse transcriptase inhibitor (NRTI) class, AZT and sta-
vudine (d4T) are both thymidine analogues that select 
for the same resistance mutations, and there is cross-
resistance between them. Generally, however, there is 
unlikely to be much NRTI cross-resistance after failing 
a first regimen.21 With the currently available NNRTIs, on 
the other hand, there is a high level of cross-resistance. 
If a patient fails nevirapine (NVP), there will be high-level 
resistance to efavirenz (EFV). The new second-genera-
tion NNRTI etravirine (ETR), which will soon be available 
in South Africa, needs a few NNRTI mutations before 
there is high-level resistance against it. Unfortunately, 
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genotyping is necessary to ascertain whether ETR will be 
active after failing an NNRTI.
Cross-resistance in the protease inhibitors (PIs) depends 
on the PI concerned. Some PIs, e.g. atazanavir, ampre-
navir and nelfinavir, develop specific primary mutations 
first without conferring cross-resistance to other PIs. 
Secondary mutations conferring cross-resistance to 
other PIs will only occur after prolonged non-suppres-
sive therapy. 
Genotyping may help to clarify whether cross-resistance 
is present. Expert advice can be invaluable in this situa-
tion.
Consider drugs used for prevention of mother-to-
child transmission (PMTCT)
Numerous studies have demonstrated resistance to NVP 
where mothers and their babies each receive one dose 
of NVP. There are emerging data in adults and infants 
suggesting reduced efficacy of future first-generation 
NNRTI-containing regimens.22-24 It is therefore advis-
able to avoid NVP and EFV as part of first-line therapy in 
this situation. Consult the Guidelines for Antiretroviral 
Therapy in Children (p. 32 of this issue) when other ARVs 
have been used for prophylaxis. 
Consider adding 3TC where M184V mutation present 
to maintain M184V mutation
Resistant HIV-1 with the hallmark 3TC resistance muta-
tion, M184V, has reduced viral fitness, i.e. it replicates at 
a reduced rate and may reverse resistance to AZT, d4T 
and tenofovir (TDF). Therefore there may be value in add-
ing in 3TC for salvage despite documented resistance.
However, the data are conflicting.25,26 ABC will also main-
tain the M184V mutation without adding in 3TC (per-
sonal communication, Professor Mark Wainberg).  
Pharmacokinetic enhancement
Where a single PI has been used previously, there may be 
a place for using a ‘boosted PI’, i.e. adding a small dose 
of ritonavir to the PI to inhibit the enzyme cytochrome 
P450 3A4, thus resulting in much higher levels of the 
PI. This may overcome minor degrees of PI resistance. 
Generally, however, it is advisable to only use boosted 
PI regimens.
Therapeutic drug monitoring (TDM)
TDM is still largely experimental in ART. However, there 
may be a place for TDM in salvage therapy with multiple 
drugs and multiple possible interactions. Contact the SA 
HIV Clinicians Society.
Dual PIs
This used to be quite ‘fashionable’ as a salvage therapy 
a few years ago. Invariably these children will have ex-
tremely high cholesterol and triglyceride levels. With the 
advent of newer agents and with data suggesting that 
dual PIs are no more efficacious than one boosted PI, 
this approach has become less popular.27,28
Mega- or giga-HAART
There are some adult data on empiric multidrug regi-
mens,29,30 but these are complex and poorly tolerated, 
and often with unfavourable drug interactions. With the 
advent of newer ARVs these regimens are no longer used 
much. A feeding gastrostomy tube may be used to sim-
plify the administration of multiple medications.31
New ARVs
Several new agents are already available overseas with 
activity against resistant virus. TDF is available in South 
Africa, but it is not used routinely in children because 
of osteopenia and nephrotoxicity. However, if properly 
monitored TDF has some merit as a salvage drug in older 
patients. New PIs such as darunavir32 and tipranavir33 
have revolutionised the management of highly resistant 
patients overseas. Raltegravir will be the first integrase 
inhibitor to be launched in South Africa. This potent and 
well-tolerated agent has shown phenomenal results in 
both naïve and ART-experienced adults.34,35 Paediatric 
studies are ongoing.36 
Etravirine, the second-generation NNRTI, may still be ac-
tive in the face of resistance to first-line NNRTIs.37,38 The 
CCR5 inhibitor maraviroc will probably have limited use 
in South Africa since it is only effective in patients who 
are CCR5-tropic and requires an expensive tropism assay 
prior to initiation.39
These new agents have achieved undetectable VLs in 
heavily ARV-experienced adults in contrast to earlier sal-
vage regimens. Paediatric dosages and formulations are 
in development. Nevertheless, one can obtain Section 21 
authorisation from the Medicines Control Council. Con-
sult an expert.
Holding strategies
Not uncommonly one encounters a situation where a 
child needs to change ART but for various reasons is un-
able to. Common situations are unresolved adherence is-
sues, inability to swallow tablets, or needing a new ARV 
that lacks paediatric dosing data or formulations. If the 
CD4 count is not too low, there may be place for a ‘hold-
ing strategy’. These are only temporary solutions and 
do not replace a suppressive regimen. Holding strate-
gies include structured treatment interruptions, 3TC 
monotherapy and holding regimens. These approach-
es should only be used on the advice of an expert. 
n   Structured treatment interruptions (STIs)
There are three scenarios where one might consider 
stopping therapy:
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Infants. Since paediatric HIV infection occurs with an 
immature immune system, treating with ARVs may allow 
the immune system to mature. Thus, a baby who has had 
several months of ART and is now over 1 year of age may 
cope without ART for several years because the immune 
system is now mature enough to cope with the baby’s 
own HIV virus. The CHER study is currently looking at 
this phenomenon. Until the results of this study are pub-
lished, this is not recommended as a routine practice. 
Infants and children with immune reconstitution. 
This is a situation where the patient’s CD4 count has 
recovered but the child is now virologically failing the 
current regimen. In this situation, there may be a place 
for taking the child off all therapy and watching the CD4 
count carefully. Once the CD4 count drops below the cri-
teria for starting ART, a new regimen can be started. The 
SMART study, in adults, showed a worse outcome in pa-
tients who stopped their ART compared with those who 
remained on ART,40 but there are few paediatric data. 
PENTA11, a pilot interruption study in children, showed 
no deaths or serious clinical events on interruption for 
up to 48 weeks.41 
Multidrug-experienced children with low CD4 
counts. Adult data reveal that there is no place for STIs 
in a salvage situation.42-44 The CD4 count drops rapidly 
and the patients are at risk for opportunistic infection. 
n 3TC monotherapy
Although there are comparatively few adult data on this 
approach, 3TC monotherapy has gained popularity. There 
are data to suggest that giving 3TC monotherapy in pa-
tients failing multiple drugs results in slower disease 
progression than no therapy at all45 because of reduced 
viral fitness in virus with the M184V mutation. This can 
be attempted. The approach may have merit in patients 
failing 3TC but with good CD4 counts and unable to 
start a definitive suppressive regimen. 3TC monotherapy 
should be avoided in patients who have ever had a very 
low CD4 count (low CD4 nadir). When the CD4 drops or 
symptoms develop, the child should be placed on a fully 
suppressive regimen.
n Holding or bridging regimens 
These are simplified regimens, usually consisting of 3 or 
4 NRTIs with the purpose of maintaining resistance mu-
tations so that the virus has a reduced replicative ability. 
The aim once again is to ‘buy time’ for the child who is 
unable to start a definitive suppressive regimen. A suit-
able child would be one with extensive NRTI resistance 
but in whom you would not want to develop more PI or 
NNRTI resistance. Therefore future options are preserved. 
Since there is already extensive NRTI resistance, there is 
no worry that the child will develop more resistance to 
the NRTIs. In adults, AZT/3TC/ABC/TDF has been used.46 
In younger children, TDF can be omitted. Once again this 
approach is inappropriate for patients with a very low 
CD4 count. Once the CD4 count drops or symptoms de-
velop the child should be placed on a fully suppressive 
regimen.
Quality of life in end-stage disease
In patients without further ARV options and who are 
failing or not tolerating mega-HAART, there may be a 
place for reducing the number of drugs to make life more 
tolerable. The disease will still progress more slowly than 
if off ARVs. Consult an expert to reduce the number of 
agents to a more tolerable regimen. 3TC should always 
be included in such a regimen. As more new drugs be-
come available, this scenario is becoming less common. 
CONCLUSION
Changing ART is a highly complex field, which can have 
major impact on a child’s future if done incorrectly. It is 
therefore strongly recommended that an expert be con-
sulted before changing any child’s ART. This would apply 
equally to a child failing their first regimen. However, the 
future is rosy with wonderful new antiretroviral options 
and certainly something worth looking forward to.
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